CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026.

马萨诸塞州剑桥和丹麦哥本哈根，2026年9月24日（环球电讯社）——Hemab Therapeutics（纳斯达克股票代码：COAG）是一家处于临床阶段的生物技术公司，致力于开发革新血液凝固障碍治疗方法的疗法，以维持生命和增强人类韧性。该公司今日宣布任命Keli Walbert为其董事会成员，自2026年9月24日起生效。

Ms. Walbert will join the Board’s Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a member of the Board..

沃尔伯特女士将加入董事会审计委员会，接替阿克谢·瓦什纳夫医学博士兼哲学博士，后者将继续担任董事会成员。

“Keli's experience turning novel scientific innovations into therapies that reach patients is exactly what Hemab needs as we work to close longstanding gaps in the treatment of bleeding disorders,” said Benny Sørensen, MD, PhD, CEO of Hemab. “As we advance our pipeline toward later-stage development, her experience building the commercial capabilities that bring new therapies to people with high-unmet-need conditions will strengthen our Board at a pivotal time for Hemab.”.

Hemab 首席执行官 Benny Sørensen 医学博士、哲学博士表示：“Keli 在将新颖的科学创新转化为惠及患者的疗法方面拥有丰富的经验，这正是 Hemab 在努力弥合出血性疾病治疗领域长期存在的差距时所亟需的。随着我们推动产品管线向后期开发阶段迈进，她在构建将新疗法带给高未满足需求患者群体的商业化能力方面的经验，将在 Hemab 发展的关键时期增强我们的董事会实力。”

“We are pleased to welcome Keli to Hemab's Board of Directors. Her commercial expertise strengthens our Board as we work to bring new therapies to people living with serious, underserved bleeding disorders,” said John Maraganore, PhD, Chair of Hemab's Board of Directors. “Her success launching medicines from very common to rare diseases is a good strategic match as we advance toward key milestones across the pipeline.”.

“我们很高兴欢迎Keli加入Hemab董事会。她的商业专长增强了我们的董事会实力，因为我们致力于为患有严重且未被充分满足需求的出血性疾病的患者带来新的疗法。”Hemab董事会主席John Maraganore博士表示。“她在从常见疾病到罕见疾病的药物推出方面取得的成功，与我们在推进管线关键里程碑方面的战略高度契合。”

Ms. Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals, spanning sales and marketing, market access, patient services, advocacy, and analytics. Her therapeutic background covers immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and metabolic disease, with experience in indications of all market sizes.

沃尔伯特女士在生物制药领域拥有超过20年的商业领导经验，涵盖销售与市场营销、市场准入、患者服务、倡导事务以及数据分析。她的治疗领域背景包括免疫学、风湿病学、皮肤病学、胃肠病学、眼科学、肾脏病学、神经病学和代谢性疾病，并拥有针对各种市场规模适应症的丰富经验。

She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy and organizational development across more than 10 marketed brands. Earlier in her career, she held leadership roles at AbbVie, the American Medical Association, Abbott and United Healthcare.

她最近担任Horizon Therapeutics美国商业执行副总裁，负责监督超过10个上市品牌的商业战略和组织发展。在职业生涯早期，她在AbbVie、美国医学会、雅培和联合健康集团担任领导职务。

Over the course of her career, she led the commercial launches of HUMIRA.

在她的职业生涯中，她主导了阿达木单抗（HUMIRA）的商业化上市。

®

®

, TEPEZZA

, TEPEZZA

®

®

and DUOPA

以及 DUOPA

®

注册商标符号

. She has been recognized with the Healthcare Businesswomen's Association's Luminary Award and an MM+M Women of Distinction Award. She earned her master's degree from Northwestern University and bachelor's degree from the University of Louisville.

她荣获医疗行业女性协会（Healthcare Businesswomen's Association）颁发的“杰出人物奖”（Luminary Award）以及 MM+M “卓越女性奖”。她拥有西北大学的硕士学位和路易斯维尔大学的学士学位。

“I'm honored to join Hemab's Board at such a pivotal moment for the company,” said Ms. Walbert. “Hemab's mission to bring new options to people living with serious, high-unmet-need bleeding disorders reflects the kind of impact I've built my career around, and I look forward to helping them move their pipeline to patients as quickly and effectively as possible.”.

“在公司如此关键的时刻加入Hemab董事会，我深感荣幸。”Walbert女士表示，“Hemab致力于为患有严重且存在巨大未满足需求的出血性疾病的患者带来新的治疗选择，这一使命与我职业生涯所追求的影响力高度契合。我期待帮助他们尽快、高效地将研发管线中的产品惠及患者。”

About Hemab Therapeutics

关于 Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.

Hemab Therapeutics Holdings, Inc. 是一家处于临床阶段的生物技术公司，致力于开发革新血液凝固障碍治疗方式的疗法，以维持生命并增强人类的韧性。Hemab 的使命是为全球数百万遭受严重出血和血栓性疾病困扰的患者发现、开发并商业化创新疗法。

Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding..

Hemab 正在打造一个创新疗法产品组合，旨在填补凝血障碍治疗领域的关键空白，其中包括：Sutacimig（HMB-001），一种处于临床开发阶段的双特异性抗体，用于预防性治疗格兰茨曼血栓无力症和因子 VII 缺乏症；HMB-002，一种处于临床开发阶段的单价抗体，用于预防性治疗血管性血友病；以及 HMB-003，一种靶向抑制纤溶酶的抗纤溶药物，处于临床开发阶段，用于治疗月经过多。

Learn more at

了解更多，请访问

hemab.com

hemab.com

. Follow us on

. 在关注我们

LinkedIn

领英

,

，

Facebook

脸书

,

，

Instagram

Instagram

, and

，和

X

X

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, and the clinical potential of sutacimig, HMB-002 and HMB-003, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿包含涉及重大风险和不确定性的前瞻性陈述。除历史事实陈述外，本新闻稿中的所有陈述，包括关于Hemab的战略、未来运营、前景和计划、管理层目标以及sutacimig、HMB-002和HMB-003的临床潜力的陈述，均构成1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。

The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

“anticipate”（预期）、“believe”（相信）、“continue”（继续）、“could”（可能）、“estimate”（估计）、“expect”（期望）、“intend”（打算）、“may”（可以）、“might”（也许）、“objective”（目标）、“ongoing”（持续中的）、“plan”（计划）、“predict”（预测）、“project”（规划）、“potential”（潜在）、“should”（应该）或“would”（将会）等词语，或其否定形式，或其他类似术语，旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别性词语。

Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to.

Hemab 可能实际上无法实现这些前瞻性陈述中披露的计划、意图或预期，您不应过度依赖这些前瞻性陈述。由于各种重要因素，实际结果或事件可能与这些前瞻性陈述中披露的计划、意图和预期存在重大差异，这些因素包括：在识别和开发候选产品过程中固有的不确定性，包括临床前研究和临床试验的启动和完成；临床前研究和临床试验结果的可获得性和时间的不确定性；Hemab 启动临床试验并招募患者入组的时间及其能力；临床前研究和早期临床试验的结果是否具有对后期临床试验结果的预测性；以及 Hemab 的现金资源是否充足。

Media:

媒体：

Deerfield Group

迪尔菲尔德集团

Peg Rusconi

佩格·鲁斯科尼

peg.rusconi@deerfieldgroup.com

peg.rusconi@deerfieldgroup.com

Investors:

投资者：

Hemab Therapeutics

Hemab 治疗公司

Mads Behrndt

马兹·贝恩特

investors@hemab.com

investors@hemab.com